Toll Free: 1-888-928-9744

NicOx S.A. - Product Pipeline Review - 2014

Published: Jul, 2014 | Pages: 36 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

NicOx S.A. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'NicOx S.A. - Product Pipeline Review - 2014', provides an overview of the NicOx S.A.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of NicOx S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of NicOx S.A. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of NicOx S.A.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the NicOx S.A.'s pipeline products

Reasons to buy

- Evaluate NicOx S.A.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of NicOx S.A. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the NicOx S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of NicOx S.A. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of NicOx S.A.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of NicOx S.A. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
NicOx S.A. Snapshot 5
NicOx S.A. Overview 5
Key Information 5
Key Facts 5
NicOx S.A. - Research and Development Overview 6
Key Therapeutic Areas 6
NicOx S.A. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
NicOx S.A. - Pipeline Products Glance 11
NicOx S.A. - Late Stage Pipeline Products 11
Filing rejected/Withdrawn Products/Combination Treatment Modalities 11
NicOx S.A. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
NicOx S.A. - Drug Profiles 14
naproxcinod 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
NCX-1021 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
NCX-1047 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
NCX-250 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
NCX-422 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
NCX-429 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
NCX-434 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
NCX-466 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Small Molecules to Activate sGC for Cardiovascular Disease 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Small Molecules to Activate sGC for Ophthalmology 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
NicOx S.A. - Pipeline Analysis 25
NicOx S.A. - Pipeline Products by Target 25
NicOx S.A. - Pipeline Products by Route of Administration 26
NicOx S.A. - Pipeline Products by Molecule Type 27
NicOx S.A. - Pipeline Products by Mechanism of Action 28
NicOx S.A. - Recent Pipeline Updates 29
NicOx S.A. - Dormant Projects 31
NicOx S.A. - Discontinued Pipeline Products 32
Discontinued Pipeline Product Profiles 32
NCX-1000 32
naproxcinod 32
NCX-1000 32
NCX-1236 32
NCX-226 33
NCX-285 33
NCX-6560 33
NicOx S.A. - Locations And Subsidiaries 34
Head Office 34
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 36
Disclaimer 36
List of Tables
NicOx S.A., Key Information 5
NicOx S.A., Key Facts 5
NicOx S.A. - Pipeline by Indication, 2014 8
NicOx S.A. - Pipeline by Stage of Development, 2014 9
NicOx S.A. - Monotherapy Products in Pipeline, 2014 10
NicOx S.A. - Filing rejected/Withdrawn, 2014 11
NicOx S.A. - Preclinical, 2014 12
NicOx S.A. - Discovery, 2014 13
NicOx S.A. - Pipeline by Target, 2014 25
NicOx S.A. - Pipeline by Route of Administration, 2014 26
NicOx S.A. - Pipeline by Molecule Type, 2014 27
NicOx S.A. - Pipeline Products by Mechanism of Action, 2014 28
NicOx S.A. - Recent Pipeline Updates, 2014 29
NicOx S.A. - Dormant Developmental Projects,2014 31
NicOx S.A. - Discontinued Pipeline Products, 2014 32 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify